Cancer Invasion and Metastasis

项目概要/摘要 癌症侵袭和转移计划（CIM）是西德尼·金梅尔（Sidney Kimmel） 综合癌症中心（SKCCC）。CIM的启动是为了阐明和瞄准驱动 转移，因为转移是患者结果的主要驱动因素。该计划包括高度 有成就的基础科学家与工程师和转化医学科学家合作。的 联合领导人是Andrew Ewald博士。（基础，入侵重点）; Ashani Weeraratna，博士（基本，肿瘤） 微环境聚焦）;和M.D.，博士（基础/临床，复发性疾病集中）。CIM是 由42名会员（31名正式会员和11名准会员）组成，分别来自三所学校和16所 约翰霍普金斯大学的所有院系。教师隶属于整个学校的四个T-32培训赠款 医学院、公共卫生学院和工程学院。与癌症直接相关的同伴总数 审查资金为1410万美元，其中830万美元来自国家癌症研究所。的总数 计划成员的出版物为768种，其中129种（16.8%）为计划内出版物，412种（53.8%）为计划间出版物， 方案和487（63.4%）有外部合作。在这些出版物中，20.6%发表在期刊上， 影响因子>10和影响因子>25的期刊占5.7%。该计划的目标是：目标1： 阐明调节个体和集体癌细胞运动的分子和细胞机制， 使用尖端的模型和工具进行器官部位的侵入。目的2：确定癌症的调控 通过肿瘤微环境的细胞、分子和机械特征发挥功能。调查人员的目标 并破坏癌细胞和促进转移的微环境之间的串扰， 生理相关模型（例如，类器官，3D皮肤重建，细胞衍生基质，人源化 动物模型）。目的3：确定和破坏复发性癌症在细胞和组织中的根本原因。 分子水平通过靶向癌症治疗成功的障碍，包括治疗耐药性、肿瘤 休眠和复发性疾病。SKCCC在这些目标上的研究成功至关重要 资源（肿瘤学组织和成像服务、实验和计算基因组学、流量/质量 细胞计数和技术开发，以及质谱分子成像和多组学）。 项目成员领导P01赠款，以了解治疗抗性的微环境调节， 转移的黑色素瘤，和U 54，整合物理科学和翻译的观点， 了解癌症侵袭。成员还参加三个SPORE（前列腺，GI，头颈部）和六个SPORE MPI U 01赠款。

PROJECT SUMMARY/ABSTRACT The Cancer Invasion and Metastasis Program (CIM) is a new Program within the Sidney Kimmel Comprehensive Cancer Center (SKCCC). CIM was launched to elucidate and target the mechanisms driving metastasis, as metastasis is the major driver of patient outcomes. The Program consists of highly accomplished basic scientists working collaboratively with engineers and translational physician-scientists. The Co-Leaders are Andrew Ewald, Ph.D. (basic, invasion focused); Ashani Weeraratna, Ph.D. (basic, tumor microenvironment focused); and Phuoc Tran, M.D., Ph.D (basic/clinical, recurrent disease focused). CIM is comprised of 42 Members (31 Full Members and eleven Associate Members) from three schools and 16 departments at Johns Hopkins University. Faculty are affiliated with four T-32 training grants across the School of Medicine, School of Public Health, and School of Engineering. The total direct cancer-relevant peer- reviewed funding is $14.1 million, with $8.3 million from the National Cancer Institute. The total number of publications by Program members is 768, of which 129 (16.8%) are Intra-Programmatic, 412 (53.8%) are Inter- Programmatic and 487 (63.4%) have external collaborations. Of these publications, 20.6% are in journals with impact factors >10 and 5.7% in journals with impact factors >25. The Aims of the Program are: Aim 1: To elucidate the molecular and cellular mechanisms regulating individual and collective cancer cell motility and invasion across organ sites using cutting-edge models and tools. Aim 2: To define the regulation of cancer function by the cellular, molecular and mechanical features of the tumor microenvironment. Investigators target and disrupt the crosstalk between the cancer cell and the metastasis-promoting microenvironment using physiologically relevant models (e.g., organoids, 3D skin reconstruction, cell-derived matrices, humanized animal models). Aim 3: To determine and disrupt the underlying cause of recurrent cancer at the cellular and molecular level by targeting barriers to therapeutic success in cancer, including therapy resistance, tumor dormancy and recurrent disease. Research success across these aims is critically enabled by SKCCC Shared Resources (Oncology Tissue and Imaging Services, Experimental and Computational Genomics, Flow/Mass Cytometry and Technology Development, and Mass Spectrometry Molecular Imaging and Multi-Omics). Program members lead a P01 grant to understand microenvironmental regulation of therapy resistance and metastasis in melanoma, and a U54 that integrates physical science and translational perspectives to understand cancer invasion. Members also participate in three SPOREs (Prostate, GI, Head and Neck) and six MPI U01 grants.